alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.4460 Neurosurgical head holder (skull clamp). ( a ) *Identification.* A neurosurgical head holder (skull clamp) is a device used to clamp the patient's skull to hold head and neck in a particular position during surgical procedures.
( b ) *Classification.* Class II (performance standards).
<PAGE>   1
                                [KPMG LETTERHEAD]



                CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS



The Board of Directors
Mosaix, Inc.:

We consent to incorporation by reference in the registration statements (Nos.
333-53677, 333-18577, 33-93948, 33-88544, 33-51620, 33-41199, 33-41197, and
33-36617) on Form S-8 of Mosaix, Inc. and subsidiaries (Company) of our reports
dated January 29, 1999 relating to the consolidated balance sheets of the
Company as of December 31, 1998 and 1997, and the related/consolidated
statements of income and comprehensive income, shareholders' equity, and cash
flows and the related financial statement schedule for each of the years in the
three-year period ended December 31, 1998, which reports appear in the 
December 31, 1998 annual report on Form 10-K of the Company.

/s/ KPMG LLP

Seattle, Washington
March 11, 1999
December 15 , 2016



### JUDGMENT 

## The Fourteenth Court of Appeals

RUFUS FREDERIC KIRBY , Appellant

NO. 14

- 16

- 00865

- CR V.

THE STATE OF TEXAS , Appellee

________________________________ This cause was heard on the transcript of the record of the court below. The record indicates that the appeal should be DISMISS ED. The Court orders the appeal DISMISSED in accordance with its opinion.
We further order this decision certified below for observance.
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4950 Manual operating table and accessories and manual operating chair and accessories. ( a ) *Identification.* A manual operating table and accessories and a manual operating chair and accessories are nonpowered devices, usually with movable components, intended to be used to support a patient during diagnostic examinations or surgical procedures.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.
[53 FR 23872, June 24, 1988, as amended at 54 FR 13828, Apr. 5, 1989; 59 FR 63010, Dec. 7, 1994; 66 FR 38803, July 25, 2001]
U.S. GOVERNMENT PUBLISHING OFFICE

WASHINGTON : 

1 

69–012 2017

115th Congress, 1st Session – – – – – – – – – – – – – House Document 115–38 

DESIGNATION OF FUNDING AS AN EMERGENCY 

REQUIREMENT 

COMMUNICATION 

FROM

THE PRESIDENT OF THE UNITED STATES 

TRANSMITTING

DESIGNATING AS EMERGENCY REQUIREMENTS ALL FUNDING SO 

DESIGNATED BY THE CONGRESS, PURSUANT TO THE CONSOLIDATED APPROPRIATIONS ACT, 2017, SEC. 6(a) 

MAY 8, 2017.—Referred to the Committee on Appropriations and ordered 

to be printed 


SSpencer on DSK4SPTVN1PROD with REPORTSE:\Seals\Congress.#13

SSpencer on DSK4SPTVN1PROD with REPORTS
(1) 

THE WHITE HOUSE, 

Washington, May 5, 2017. 

Hon. PAUL D. RYAN, 

Speaker of the House of Representatives, 

Washington, DC. 

DEAR MR. SPEAKER: In accordance with section 6(a) of the Consolidated Appropriations Act, 2017 (the ‘‘Act’’), I hereby designate 

as emergency requirements all funding (including the rescission of 

funds) so designated by the Congress in the Act pursuant to section 

251(b)(2)(A) of the Balanced Budget and Emergency Deficit Control 

Act of 1985, as amended, as outlined in the enclosed list of accounts. 

The details of this action are set forth in the enclosed memorandum from the Director of the Office of Management and Budget. 

Sincerely, 

DONALD J. TRUMP. 


SSpencer on DSK4SPTVN1PROD with REPORTS
2 


SSpencer on DSK4SPTVN1PROD with REPORTSInsert offset folio 3 here HD38.001
3 


SSpencer on DSK4SPTVN1PROD with REPORTSInsert offset folio 4 here HD38.002
# C_2014235EN.01002502.xml

| 21.7.2014 | EN | Official Journal of the European Union | C 235/25 |
| --- | --- | --- | --- |

21.7.2014

EN

Official Journal of the European Union

C 235/25

---

Action brought on 24 April 2014 — Bionecs/OHMI — Fidia Farmaceutici (BIONECS)

(Case T-262/14)

2014/C 235/35

Language in which the application was lodged: English

Parties

Parties

Applicant: Bionecs GmbH (Munich, Germany) (represented by: M. Knitter, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Other party to the proceedings before the Board of Appeal: Fidia Farmaceutici SpA (Abano Terme, Italy)

Other party to the proceedings before the Board of Appeal:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | Annul the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 6 February 2014 given in Case R 1179/2013-1; |
| --- | --- |

—

Annul the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 6 February 2014 given in Case R 1179/2013-1;

| — | Order the defendant to pay the costs of proceedings. |
| --- | --- |

—

Order the defendant to pay the costs of proceedings.

Pleas in law and main arguments

Pleas in law and main arguments

Applicant for a Community trade mark: The applicant

Applicant for a Community trade mark:

Community trade mark concerned: The word mark ‘BIONECS’ for goods and services in classes 5, 29 and 35 — Community trade mark application No 1 0 6 50  638

Community trade mark concerned:

Proprietor of the mark or sign cited in the opposition proceedings: The other party to the proceedings before the Board of Appeal

Proprietor of the mark or sign cited in the opposition proceedings:

Mark or sign cited in opposition: The word mark ‘BIONECT’ for goods in class 5 registered as international trade mark under the number 7 15  915

Mark or sign cited in opposition:

Decision of the Opposition Division: Upheld the opposition in part

Decision of the Opposition Division:

Decision of the Board of Appeal: Dismissed the appeal

Decision of the Board of Appeal:

Pleas in law: Infringement of Article 8(1)(b) CTMR

Pleas in law:

---
**EXHIBIT 32.1**

 

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350,**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF2002**

** **

In connection with EMRISE Corporation’s (the “Company”) Quarterly Report on Form 10-Qfor the period ended March 31, 2010, as filed with the U.S. Securities andExchange Commission on the date hereof (the “Report”), the undersigned herebycertifies in his capacity as Chief Executive Officer, pursuant to18 U.S.C. section 1350, as adopted pursuant to Section 906 of theSarbanes-Oxley Act of 2002, that based on his knowledge:

 

1.             theReport fully complies with the requirements of Section 13(a) or 15(d) ofthe Securities Exchange Act of 1934, as amended; and

 

2.             theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company.

 
| Dated: May 17, 2010 | By:    | /s/ CARMINE T. OLIVA                                   |
|--------------------------|--------|--------------------------------------------------------|
|                     |   | Carmine T. Oliva                                       |
|                     |   | Chief Executive Officer (Principal Executive  Officer) |

 

 

*A signed original of this written statement required by Section 906,or other document authenticating, acknowledging, or otherwise adopting thesignature that appears in typed form within the electronic version of thiswritten statement required by Section 906, has been provided to theCompany and will be retained by the Company and furnished to the U.S.Securities and Exchange Commission or its staff upon request.*

 

----
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.4790 Ophthalmic sponge. ( a ) *Identification.* An ophthalmic sponge is a device that is an absorbant sponge, pad, or spear made of folded gauze, cotton, cellulose, or other material intended to absorb fluids from the operative field in ophthalmic surgery.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 886.9.
[52 FR 33355, Sept. 2, 1987, as amended at 84 FR 71817, Dec. 30, 2019]
##### 



EXHIBIT 31.2
 Certification Pursuant To
Rules 13a-14(a) And 15d-14(a) Under The Securities Exchange Act Of 1934, As Amended
  1.
    
    I have reviewed this quarterly report on Form 10-Q of Biopure Corporation (the
Registrant);2.
    
    Based on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;3.
    
    Based on my knowledge, the financial statements, and other financial information
included in this quarterly report, fairly present in all material respects the financial
condition, results of operations and cash flows of the Registrant as of, and for, the periods
presented in this report;4.
    
    The Registrants other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the Registrant and have:
     5.
    
    The Registrants other certifying officer and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the Registrants auditors and the
audit committee of the Registrants board of directors (or persons performing the equivalent
functions):
   Date: September 11, 2006
    
    /s/ Francis H. MurphyFrancis H. MurphyChief Financial Officer
§ 582.3795 Sodium sorbate. ( a ) *Product.* Sodium sorbate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
# C_2016027EN.01004501.xml

| 25.1.2016 | EN | Official Journal of the European Union | C 27/45 |
| --- | --- | --- | --- |

25.1.2016

EN

Official Journal of the European Union

C 27/45

---

Judgment of the General Court of 3 December 2015 — Compagnie des fromages & Richesmonts v OHIM (representation of a red and white Vichy motif)

(Case T-327/14) (1)

1

((Community trade mark - Invalidity proceedings - Community figurative mark representing a red and white Vichy motif - Lack of distinctive character - Article 7(1)(b) of Regulation (EC) No 207/2009))

(2016/C 027/55)

Language of the case: French

Parties

Parties

Applicant: Compagnie des fromages & Richesmonts (Puteaux, France) (represented by: T. Mollet-Viéville and T. Cuche, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented initially by: V. Melgar, and subsequently by: J. Crespo Carillo, acting as Agents)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM, intervening before the General Court: Grupo Lactalis Iberia SA (Madrid, Spain) (represented by: D. Masson, lawyer)

Other party to the proceedings before the Board of Appeal of OHIM, intervening before the General Court:

Re:

Re:

Action brought against the decision of the Fourth Board of Appeal of OHIM of 2 March 2014 (Case R 1295/2012-4) concerning invalidity proceedings between Grupo Lactalis Iberia SA and Compagnie des fromages & Richesmonts.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Compagnie des fromages & Richesmonts to pay the costs. |
| --- | --- |

2.

Orders Compagnie des fromages & Richesmonts to pay the costs.

---

(1)  OJ C 235, 21.7.2014.

1

---
<TABLE> <S> <C>

<ARTICLE> 9
<MULTIPLIER> 1
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          SEP-30-1998
<PERIOD-START>                             OCT-01-1997
<PERIOD-END>                               SEP-30-1998
<CASH>                                         541,682
<INT-BEARING-DEPOSITS>                       1,245,446
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                 88,994,646
<INVESTMENTS-CARRYING>                      18,163,263
<INVESTMENTS-MARKET>                        18,207,400
<LOANS>                                    109,417,586
<ALLOWANCE>                                  (449,000)
<TOTAL-ASSETS>                             228,032,722
<DEPOSITS>                                 115,698,518
<SHORT-TERM>                                11,800,000
<LIABILITIES-OTHER>                          2,681,029
<LONG-TERM>                                 50,000,000
<PREFERRED-MANDATORY>                           39,814
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                  45,214,370
<TOTAL-LIABILITIES-AND-EQUITY>             228,032,722
<INTEREST-LOAN>                              8,387,749
<INTEREST-INVEST>                            8,196,004
<INTEREST-OTHER>                                     0
<INTEREST-TOTAL>                            16,583,753
<INTEREST-DEPOSIT>                           6,333,665
<INTEREST-EXPENSE>                          10,013,258
<INTEREST-INCOME-NET>                        6,570,495
<LOAN-LOSSES>                                  146,876
<SECURITIES-GAINS>                             570,564
<EXPENSE-OTHER>                              4,994,546
<INCOME-PRETAX>                              2,354,935
<INCOME-PRE-EXTRAORDINARY>                   1,927,735
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,927,735
<EPS-PRIMARY>                                      .67
<EPS-DILUTED>                                      .65
<YIELD-ACTUAL>                                    2.93
<LOANS-NON>                                    562,000
<LOANS-PAST>                                         0
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                               332,000
<CHARGE-OFFS>                                       30
<RECOVERIES>                                         0
<ALLOWANCE-CLOSE>                              449,000
<ALLOWANCE-DOMESTIC>                           449,000
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0
        

</TABLE>
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1110 Bilirubin (total or direct) test system. ( a ) *Identification.* A bilirubin (total or direct) test system is a device intended to measure the levels of bilirubin (total or direct) in plasma or serum. Measurements of the levels of bilirubin, an organic compound formed during the normal and abnormal distruction of red blood cells, if used in the diagnosis and treatment of liver, hemolytic hematological, and metabolic disorders, including hepatitis and gall bladder block.
( b ) *Classification.* Class II.
STEAM ELECTRIC CBI REPLACEMENT PAGE

EPA-HQ-OW-2009-0819

DCN: SE03511

THE FOLLOWING HAS BEEN REMOVED BECAUSE IT CONTAINS CONFIDENTIAL BUSINESS INFORMATION (CBI) PER 40 CFR PART 2, SUBPART B.
### D ISTRICT 

### C OURT 

### O F 

### A PPEAL 

### O F 

### T HE 

### S TATE 

### O F 

### F LORIDA
F OURTH D ISTRICT

HUGH MESSEC , a/k/a JOE R. HOPKINS , Appellant,

v.

STATE OF FLORIDA , Appellee

.

No. 4D 18

- 2370

[ July 18, 2019 ]

Appeal from the Circuit Court for the Seventeenth Judicial Circuit, Broward County ; Barbara McCarthy , Judge; L.T. Case No. 91

- 7274CF10A

.
Joe R. Hopkins, Raiford, pro se.

Ashley Moody, Attorney General, Tallahassee, and Jeanine Germanowicz, Assistant Attorney General, West Palm Beach, for appellee.

P ER C URIAM

.
Affirmed

.

W ARNE R , D AMOORGIAN and C IKLIN , JJ., concur.

* * *

Not final until disposition of timely filed motion for rehearing.
Exhibit 32.1



Certification Pursuant to § 906 of the Sarbanes-Oxley Act of 2002



Pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the
Sarbanes-Oxley Act of 2002, in connection with the filing of the Form 10-Q of STERIS Corporation for the quarter ended June 30, 2004, as filed with the Securities and Exchange Commission on the date hereof (the Report), each of the
undersigned officers of the Company certifies, that, to such officers knowledge:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the
periods expressed in the Report.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



A signed
original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section
906, has been provided to STERIS Corporation and will be retained by STERIS Corporation and furnished to the Securities and Exchange Commission or its staff upon request.



/s/ Les C. VinneyName:

Les C. VinneyTitle:

President and Chief Executive Officer/s/ Laurie BrlasName:

Laurie BrlasTitle:

Senior Vice President and Chief Financial Officer




Dated: August 9, 2004
# C_2016078EN.01001801.xml

| 29.2.2016 | EN | Official Journal of the European Union | C 78/18 |
| --- | --- | --- | --- |

29.2.2016

EN

Official Journal of the European Union

C 78/18

---

Judgment of the General Court of 14 January 2016 — International Gaming Projects v OHIM (BIG BINGO)

(Case T-663/14) (1)

1

((Community trade mark - Application for Community figurative mark BIG BINGO - Absolute ground for refusal - Distinctive character - Article 7(1)(b) of Regulation (EC) No 207/2009))

(2016/C 078/27)

Language of the case: Spanish

Parties

Parties

Applicant: International Gaming Projects Ltd (Valetta, Malta) (represented by: M. D. Garayalde Niño, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: V. Melgar, acting as Agent)

Defendant:

Re:

Re:

Action brought against the decision of the First Board of Appeal of OHIM of 11 June 2014 (Case R 755/2014-1) concerning an application for registration of the figurative sign BIG BINGO as a Community trade mark.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders International Gaming Projects Ltd to pay the costs. |
| --- | --- |

2.

Orders International Gaming Projects Ltd to pay the costs.

---

(1)  OJ C 395, 10.11.2014.

1

---
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.4380 Cardiopulmonary bypass pump speed control. ( a ) *Identification.* A cardiopulmonary bypass pump speed control is a device used that incorporates an electrical system or a mechanical system, or both, and is used to control the speed of blood pumps used in cardiopulmonary bypass surgery.
( b ) *Classification.* Class II (performance standards).
EXHIBIT 32.2SECTION 1350 CERTIFICATION     I, Edward P. Smolyansky, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant toSection 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Lifeway Foods, Inc.(the “Company”) on Form 10-QSB for three-month period ended June 30, 2006:     (1) Fully complies with the requirements of section 13(a) or 15(d) of the SecuritiesExchange Act of 1934; and     (2) that the information contained in the report fairly presents, in all materialrespects, the financial condition and results of operations of the Company.     This written statement is being furnished to the Securities and Exchange Commission as anexhibit to such Form 10-QSB. A signed original of this written statement required by Section 906has been provided to the Company and will be retained by the Company and furnished to theSecurities and Exchange Commission or its staff upon request.Date: August 14, 2006       /s/ Edward P. Smolyansky     Chief Financial and Accounting Officerand Treasurer
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                       5,741,525
<SECURITIES>                                45,876,225
<RECEIVABLES>                                6,186,914
<ALLOWANCES>                                         0
<INVENTORY>                                  5,636,495
<CURRENT-ASSETS>                            70,188,125
<PP&E>                                       2,131,128
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              73,529,835
<CURRENT-LIABILITIES>                       13,999,914
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       192,946
<OTHER-SE>                                  59,336,975
<TOTAL-LIABILITY-AND-EQUITY>                73,529,835
<SALES>                                     30,582,086
<TOTAL-REVENUES>                            30,582,086
<CGS>                                       12,310,078
<TOTAL-COSTS>                               31,951,533
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                           (11,438,912)
<INCOME-TAX>                               (2,101,139)
<INCOME-CONTINUING>                        (9,337,773)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (9,337,773)
<EPS-BASIC>                                     (0.60)
<EPS-DILUTED>                                   (0.60)


</TABLE>
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.4290 Cardiopulmonary bypass adaptor, stopcock, manifold, or fitting. ( a ) *Identification.* A cardiopulmonary bypass adaptor, stopcock, manifold, or fitting is a device used in cardiovascular diagnostic, surgical, and therapeutic applications to interconnect tubing, catheters, or other devices.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.
[45 FR 7907, Feb. 5, 1980, as amended at 84 FR 71812, Dec. 30, 2019]